Definium Therapeutics Reports Third-Quarter 2026 Financial Results
Definium Therapeutics reported financial results for the quarter ended in its third-quarter 2026 report.
Story updates
09:01:27 PM UTC
SquawkNews
Definium reported $1.05B in cash, cash equivalents and investments as of September 30, 2026, versus $411.6M on December 31, 2025, and said funds are expected to support operations into 2030. Net loss was $51.0M versus $67.3M a year earlier; initial DT402 Phase 2a results were positive.Material Deta…
09:15:37 PM UTC
SquawkNews
Definium Therapeutics Reports $51.0 Million Q3 Net Loss and DT120 Phase 3 Progress
Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ende…